Health
Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures
Philips RADIQAL trial May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the
About this update from Koninklijke Philips N.v.
[{"type":"image","alt":"Royal Philips","displaySize":"","headline":null,"caption":"Royal Philips","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/e89b2492268f247076ffcde3cdf98919"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gAicZ00NXenNt1pULlYKVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e89b2492268f247076ffcde3cdf98919","width":300,"height":55}},"lazy":false},{"type":"text","content":"Philips RADIQAL trial","length":21,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":7571,"height":5679,"url":"https://media.zenfs.com/en/globenewswire.com/01baed84df72dc98f52fb1cf1d9d2183"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/maeiavoFhx8OyX4cfeL7Eg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/01baed84df72dc98f52fb1cf1d9d2183","width":960,"height":720},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fEUQOmCTtFQpVxLORYknXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xODAwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/01baed84df72dc98f52fb1cf1d9d2183","width":1200,"height":900}}},{"type":"text","content":"May 20, 2025","length":12,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance.","length":151,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":326,"olType":false},{"type":"text","content":"Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the...